when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

BRISTOL · news · pharmadog

← back to BRISTOL

News mentioning BRISTOL

354 stories

Aug 18, 26STAT+: Pharmalittle: We’re reading about a setback for Eyepoint, a win for Amylyx, and morestat

Aug 18, 26STAT+: Amylyx endocrine drug succeeds in pivotal studystat

Aug 18, 26STAT+: A pill that mimics exercise? Early results on drug designed to maintain both weight loss and muscle massstat

Aug 17, 26STAT+: Eyepoint study results for vision treatment disappoint, but company still sees promisestat

Aug 17, 26AstraZeneca scraps Phase 3 trial of new bispecific in lung cancerbiopharma dive

Aug 17, 26STAT+: Akeso and Summit’s lung cancer drug shows worsening tumor-progression benefitstat

Aug 17, 26STAT+: Pharmalittle: We’re reading about an AstraZeneca setback, falling U.S. drug prices, and morestat

Aug 17, 26AstraZeneca ends phase 3 lung cancer trial after bispecific falls short versus Keytrudafiercebiotech

Aug 14, 26Cytokinetics brings patent suit against Bristol Myers, escalating rivalryendpoints

Aug 14, 26STAT+: Up and down the ladder: The latest comings and goingsstat

Aug 14, 26Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgenebiopharma dive

Aug 14, 26STAT+: PBMs agree to display TrumpRx drug pricesstat

Aug 14, 26STAT+: Pharmalittle: We’re reading about a lawsuit over lab tests for meds, a Bristol myeloma drug, and morestat

Aug 14, 26Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myersbiopharma dive

Aug 14, 26STAT+: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug classstat

Aug 14, 26BMS welcomes new multiple myeloma drug as generics batter current portfoliobiospace

Aug 14, 26MapLight dims preclinical programs to make phase 3-ready schizophrenia drug shine brighterfiercebiotech

Aug 13, 26FDA approves Bristol Myers' multiple myeloma successorendpoints

Aug 12, 26With tech backing, AI biotechs force biopharma into ‘fail-fast’ drug developmentbiospace

Aug 11, 26AbbVie, Novartis and Bristol Myers file 340B lawsuits in Illinoisendpoints

Aug 10, 26Bristol Myers details new $2.3B manufacturing campus in Houstonendpoints

Aug 10, 26BMS picks Texas for new $2.3B manufacturing campusbiospace

Aug 10, 26MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trialfiercebiotech

Aug 10, 26As BMS’ Cobenfy struggles to gain traction, MapLight knocks on the doorbiospace

Aug 10, 26Recon: BMS plans $2.3B Houston manufacturing site; MHRA approves Lilly weight-loss drug for weight loss, type 2 diabetesraps

Aug 7, 26Why Big Pharma is chasing the industry’s most-powerful supercomputerbiopharma dive

Aug 6, 26Replimune rebounds to win FDA approval of melanoma drugbiopharma dive

Aug 6, 26Third time’s the charm for Replimune as melanoma drug earns FDA greenlightbiospace

Aug 6, 26Braveheart pumps more life into biotech IPO market with $382M expected debutbiospace

Aug 6, 26STAT+: Pharmalittle: We’re reading about Moderna’s flu shot, a death in a gene-editing trial in China, and morestat

← prevpage 7 of 12next →